1. Home
  2. SLVM vs REPL Comparison

SLVM vs REPL Comparison

Compare SLVM & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sylvamo Corporation

SLVM

Sylvamo Corporation

HOLD

Current Price

$34.79

Market Cap

1.7B

ML Signal

HOLD

Logo Replimune Group Inc.

REPL

Replimune Group Inc.

HOLD

Current Price

$12.80

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLVM
REPL
Founded
1898
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Paper
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.4B
IPO Year
2021
2018

Fundamental Metrics

Financial Performance
Metric
SLVM
REPL
Price
$34.79
$12.80
Analyst Decision
Strong Buy
Hold
Analyst Count
3
9
Target Price
$54.00
$5.67
AVG Volume (30 Days)
198.2K
2.4M
Earning Date
05-08-2026
05-21-2026
Dividend Yield
4.15%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,351,000,000.00
N/A
Revenue This Year
$0.93
N/A
Revenue Next Year
$1.54
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$34.25
$1.50
52 Week High
$56.80
$16.33

Technical Indicators

Market Signals
Indicator
SLVM
REPL
Relative Strength Index (RSI) 41.07 43.79
Support Level $34.25 $6.81
Resistance Level $40.13 $16.02
Average True Range (ATR) 1.16 0.79
MACD -0.03 -0.47
Stochastic Oscillator 31.45 18.07

Price Performance

Historical Comparison
SLVM
REPL

About SLVM Sylvamo Corporation

Sylvamo Corp is an uncoated papers company with a broad portfolio of top-tier brands and low-cost, large-scale paper mills. It produces uncoated freesheet (UFS) for paper products such as cut size and offset paper, as well as market pulp. The company offers Copy and Printer papers, Commercial Printing papers, Converting papers, and Specialty papers. It operates in three geographical segments: Europe, Latin America, and North America. Key revenue is generated from North America.

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.

Share on Social Networks: